专利号:US-9353057-B2 优先权日:2003-12-30 标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof 发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA 权利人:XENOPORT INC 摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.
专利号:US-10925977-B2 优先权日:2006-10-05 标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications 发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S 权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS 摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.
专利号:US-11766432-B2 优先权日:2018-07-27 标题 :Cleavable conjugates of catechol compounds and water-soluble polymers and methods of treatment using the same 发明人:BENTLEY MICHAEL; FANG ZHIHAO; WEIMER REBECCA; VIEGAS TACEY; MOREADITH RANDALL 权利人:SERINA THERAPEUTICS INC 摘要:Described are conjugates comprising a water-soluble polymer linked to a compound comprising a catechol moiety via a cleavable linkage, wherein the cleavable linkage is formed between the water-soluble polymer and a first phenolic hydroxyl group of the catechol moiety and a second phenolic hydroxyl group of the catechol moiety is linked to a blocking group wherein the rate of hydrolytic release of the compound comprising the catechol moiety is controlled, at least in part, through structure or design of the blocking group on the second phenolic hydroxyl group of the catechol moiety. Therefore, the rate of hydrolytic release of the compound comprising the catechol moiety can be tuned through structural design of the group on the second phenolic hydroxyl group of the catechol moiety. Compounds used in the synthesis of the described conjugates and methods of using the described conjugate and other compounds in the treatment of dopamine-responsive disorders are also described.
专利号:US-2008090885-A1 优先权日:2006-10-12 标题:Preparation of losartan 5-carboxylic acid and use thereof 发明人:CHEN LIQIN; LI JIAN; SHEN YINGZHONG 权利人:CHEN LIQIN; LI JIAN; SHEN YINGZHONG 摘要:A method for synthesis of losartan 5-carboxylic acid (EXP-3174).
专利号:US-8017776-B2 优先权日:2003-07-15 标题 :Methods for synthesis of acyloxyalkyl compounds 发明人:BHAT LAXMINARAYAN; GALLOP MARK A 权利人:XENOPORT INC 摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.
专利号:US-12295961-B2 优先权日:2009-12-31 标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols 发明人:DHINGRA OM 权利人:MARIUS PHARMACEUTICALS INC 摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.
1: Ruffolo RR Jr. The pharmacology of dobutamine. Am J Med Sci. 1987 Oct;294(4):244-8. doi: 10.1097/00000441-198710000-00005. 29(4):490-498. doi: 10.5935/0103-507X.20170068. 3: Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002 Jul 20;360(9328):196-202. doi: 10.1016/s0140-6736(02)09455-2. 138(1 Pt 1):78-86. doi: 10.1016/s0002-8703(99)70250-4. 37(1):14-23. doi: 10.1007/s00246-015-1263-9. Epub 2015 Sep 7. Erratum in: Pediatr Cardiol. 2016 Dec 1;: 9(4):e95644. doi: 10.1371/journal.pone.0095644. 7: Al Madfai F, Valah B, Zaidi STR, Wanandy T, Ming LC, Peterson GM, Patel RP. Stability of dobutamine in continuous ambulatory delivery devices. J Clin Pharm Ther. 2018 Aug;43(4):530-535. doi: 10.1111/jcpt.12674. Epub 2018 Mar 2. 20(2):134. doi: 10.14744/AnatolJCardiol.2018.50708.
合成参考文献
参考文献:10.1007/s10554-010-9598-z 摘要:Innocenti F, Agresti C, Baroncini C, Caldi F, Mannucci E, Monami M, Pini R. Prognostic value of dobutamine stress echocardiography in diabetic patients. The International Journal of Cardiovascular Imaging. 2010 Feb 14;26(5):499–507. doi: 10.1007/s10554-010-9598-z. 参考文献:10.1186/cc8875 摘要:Mayer J, Boldt J, Mengistu AM, Röhm KD, Suttner S. Goal-directed intraoperative therapy based on autocalibrated arterial pressure waveform analysis reduces hospital stay in high-risk surgical patients: a randomized, controlled trial. Crit Care. 2010;14(1):R18. 参考文献:10.1007/s00259-005-1965-y 摘要:Schuijf JD, Poldermans D, Shaw LJ, Jukema JW, Lamb HJ, de Roos A, Wijns W, van der Wall EE, Bax JJ. Diagnostic and prognostic value of non-invasive imaging in known or suspected coronary artery disease. European Journal of Nuclear Medicine and Molecular Imaging. 2005 Nov 30;33(1):93–104. doi: 10.1007/s00259-005-1965-y. 参考文献:10.1186/cc10306 摘要:Konings MK, Grundeman PF, Goovaerts HG, Roosendaal MR, Hoefer IE, Doevendans PA, Rademakers FE, Buhre WF. In-vivo validation of a new non-invasive continuous ventricular stroke volume monitoring system in an animal model. Crit Care. 2011 Jul 11;15(4):R165. 参考文献:10.1007/s10741-011-9265-z 摘要:Carubelli V, Metra M, Lombardi C, Bettari L, Bugatti S, Lazzarini V, Dei Cas L. Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment. Heart Fail Rev. 2012 Mar;17(2):271–82. doi: 10.1007/s10741-011-9265-z.